CD19 is broadly and homogeneously expressed throughout B-cell differentiation, up to the stage of plasma cell, which makes it an interesting target in the treatment of B-cell lymphomas (62, 87). This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.